These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36658390)

  • 1. Chronic lymphocytic leukemia presence impairs antigen-specific CD8
    Martens AWJ; Kavazović I; Krapić M; Pack SM; Arens R; Jongejan A; Moerland PD; Eldering E; van der Windt GJW; Wensveen FM; Peters FS; Kater AP
    Leukemia; 2023 Mar; 37(3):606-616. PubMed ID: 36658390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming.
    Wu J; Xu X; Lee EJ; Shull AY; Pei L; Awan F; Wang X; Choi JH; Deng L; Xin HB; Zhong W; Liang J; Miao Y; Wu Y; Fan L; Li J; Xu W; Shi H
    Oncotarget; 2016 Jun; 7(26):40558-40570. PubMed ID: 27302925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
    Funk CR; Wang S; Chen KZ; Waller A; Sharma A; Edgar CL; Gupta VA; Chandrakasan S; Zoine JT; Fedanov A; Raikar SS; Koff JL; Flowers CR; Coma S; Pachter JA; Ravindranathan S; Spencer HT; Shanmugam M; Waller EK
    Blood; 2022 Jan; 139(4):523-537. PubMed ID: 35084470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8
    Llaó Cid L; Hanna BS; Iskar M; Roessner PM; Öztürk S; Lichter P; Zapatka M; Seiffert M
    Leuk Lymphoma; 2020 Feb; 61(2):351-356. PubMed ID: 31519123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
    Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
    Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
    Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
    Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia.
    Scrivener S; Goddard RV; Kaminski ER; Prentice AG
    Leuk Lymphoma; 2003 Mar; 44(3):383-9. PubMed ID: 12688308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
    Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.
    Biagi E; Dotti G; Yvon E; Lee E; Pule M; Vigouroux S; Gottschalk S; Popat U; Rousseau R; Brenner M
    Blood; 2005 Mar; 105(6):2436-42. PubMed ID: 15536147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia.
    Rezvany MR; Jeddi-Tehrani M; Wigzell H; Osterborg A; Mellstedt H
    Blood; 2003 Feb; 101(3):1063-70. PubMed ID: 12393705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.
    Grioni M; Brevi A; Cattaneo E; Rovida A; Bordini J; Bertilaccio MTS; Ponzoni M; Casorati G; Dellabona P; Ghia P; Bellone M; Calcinotto A
    Blood Adv; 2021 Jul; 5(14):2817-2828. PubMed ID: 34269799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
    Hanna BS; Yazdanparast H; Demerdash Y; Roessner PM; Schulz R; Lichter P; Stilgenbauer S; Seiffert M
    Haematologica; 2021 Apr; 106(4):968-977. PubMed ID: 32139435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded antigen-experienced CD160
    Bozorgmehr N; Okoye I; Oyegbami O; Xu L; Fontaine A; Cox-Kennett N; Larratt LM; Hnatiuk M; Fagarasanu A; Brandwein J; Peters AC; Elahi S
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells.
    Zaborsky N; Gassner FJ; Asslaber D; Reinthaler P; Denk U; Flenady S; Hofbauer JP; Danner B; Rebhandl S; Harrer A; Geisberger R; Greil R; Egle A
    Oncotarget; 2016 Aug; 7(31):49459-49469. PubMed ID: 27385215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of chronic lymphocytic leukemia development by clonally-expanded CD8
    Hanna BS; Roessner PM; Yazdanparast H; Colomer D; Campo E; Kugler S; Yosifov D; Stilgenbauer S; Schmidt M; Gabriel R; Lichter P; Seiffert M
    Leukemia; 2019 Mar; 33(3):625-637. PubMed ID: 30267008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells.
    Wallgren A; Festin R; Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
    Blood; 1993 Aug; 82(4):1230-8. PubMed ID: 8102559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.
    de Weerdt I; Hofland T; Lameris R; Endstra S; Jongejan A; Moerland PD; de Bruin RCG; Remmerswaal EBM; Ten Berge IJM; Liu N; van der Stelt M; Faber LM; Levin MD; Eldering E; Tonino SH; de Gruijl TD; van der Vliet HJ; Kater AP
    Blood; 2018 Nov; 132(21):2260-2272. PubMed ID: 30213872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-2 induction of Blimp-1 is a key in vivo signal for CD8+ short-lived effector T cell differentiation.
    Boulet S; Daudelin JF; Labrecque N
    J Immunol; 2014 Aug; 193(4):1847-54. PubMed ID: 25015830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in functional but not structural avidity during differentiation of CD8+ effector cells in vivo after virus infection.
    Amoah S; Yammani RD; Grayson JM; Alexander-Miller MA
    J Immunol; 2012 Jul; 189(2):638-45. PubMed ID: 22706075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.